We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
Read MoreHide Full Article
Rigel Pharmaceuticals, Inc. (RIGL - Free Report) is a clinical-stage biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on RIGL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Rigel could be a solid choice for investors.
Current Quarter Estimates for RIGL
In the past 30 days, 2 estimates have gone higher for Rigel while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 19 cents a share 30 days ago, to a loss of 12 cents today, a move of 36.8%.
Current Year Estimates for RIGL
Meanwhile, Rigel’s current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 66 cents per share 30 days ago to a loss of 50 cents per share today, an increase of 24.2%.
The stock has also started to move higher lately, adding 34.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
Rigel Pharmaceuticals, Inc. (RIGL - Free Report) is a clinical-stage biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on RIGL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Rigel could be a solid choice for investors.
Current Quarter Estimates for RIGL
In the past 30 days, 2 estimates have gone higher for Rigel while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 19 cents a share 30 days ago, to a loss of 12 cents today, a move of 36.8%.
Current Year Estimates for RIGL
Meanwhile, Rigel’s current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 66 cents per share 30 days ago to a loss of 50 cents per share today, an increase of 24.2%.
Rigel Pharmaceuticals, Inc. Price and Consensus
Rigel Pharmaceuticals, Inc. Price and Consensus | Rigel Pharmaceuticals, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 34.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>